It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Myotonic dystrophy type 1 (DM1) is a severe autosomal dominant neuromuscular disease in which the musculoskeletal system contributes substantially to overall mortality and morbidity. DM1 stems from a noncoding CTG trinucleotide repeat expansion in the DMPK gene. The human skeletal actin long repeat (HSALR) mouse model reproduces several aspects of the disease, but the muscle-wasting phenotype of this model has never been characterized in vivo. Herein, we used quantitative MRI to measure the fat and muscle volumes in the leg compartment (LC) of mice. These acquired data were processed to extract relevant parameters such as fat fraction and fat infiltration (fat LC/LC) in HSALR and control (FBV) muscles. These results showed increased fat volume (fat LC) and fat infiltration within the muscle tissue of the leg compartment (muscle LC), in agreement with necropsies, in which fatty clumps were observed, and consistent with previous findings in DM1 patients. Model mice did not reproduce the characteristic impaired fat fraction, widespread fat replacement through the muscles, or reduced muscle volume reported in patients. Taken together, the observed abnormal replacement of skeletal muscle by fat in the HSALR mice indicates that these mice partially reproduced the muscle phenotype observed in humans.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 La Fe Health Research Institute (IISLAFE), Neuromuscular Research Unit, Neurology Department, Valencia, Spain
2 Singular Scientific and Technical Infrastructures (ICTS), Biomedical Imaging Research Group (GIBI230) and “La Fe” Imaging Node of the Distributed Biomedical Imaging Network (ReDIB), Valencia, Spain; La Fe University and Polytechnic Hospital, Medical Imaging Department, Valencia, Spain
3 La Fe Health Research Institute (IISLAFE), Neuromuscular Research Unit, Neurology Department, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185); Universitat de València, Department of Medicine, Valencia, Spain (GRID:grid.5338.d) (ISNI:0000 0001 2173 938X)
4 University of Valencia, University Research Institute for Biotechnology and Biomedicine (BIOTECMED), Valencia, Spain (GRID:grid.5338.d) (ISNI:0000 0001 2173 938X); INCLIVA Biomedical Research Institute, Translational Genomics Group, Valencia, Spain (GRID:grid.429003.c) (ISNI:0000 0004 7413 8491)